Patent
Producing cells for transplantation to reduce host rejection and resulting cells
Reads0
Chats0
TLDR
In this article, a method for treating cells with E19 protein in order to alter the presentation of MHC class I cell surface antigens on these cells and thereby allow introduction of these cells into a recipient organism while reducing transplant rejection by the recipient organism's immune system is described.Abstract:
A method for treating cells with E19 protein in order to alter the presentation of MHC class I cell surface antigens on these cells and thereby allow introduction of these cells into a recipient organism while reducing transplant rejection by the recipient organism's immune system is described. The cells may be contacted with E19 protein by the presence in the cells of a vector which carries and expresses the E19 coding sequence or by the presence in the cells of a transgene with expresses the E19 coding sequence. The method may be used for treating a genetic disorder, a wound, a burn, or a disease, or for effecting gene therapy in a recipient organism. Transgenic and chimeric organisms, and cells are also provided.read more
Citations
More filters
Patent
Thymidine kinase mutants
TL;DR: In this article, isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations were provided, at least one of the mutations encoding an amino acid substitution upstream from a DRH nucleoside binding site.
Patent
Improved methods for transplantation using modified cells and t cell inhibitory agents
TL;DR: Improved methods for inhibiting rejection of transplanted cells in an allogeneic or xenogeneic recipient subject are described in this paper, which involve altering at least one antigen on the surface of a donor cell prior to transplantation to reduce the immunogenicity of the cell in a recipient subject.
Patent
Medicinal combination useful for in vivo exogenic transfection and expression
Michel Perricaudet,Lee Martin,Lucienne Chatenoud,Haddada Hedi,Jean-François Bach,Webb Michelle +5 more
TL;DR: In this article, a combination of at least one immunosuppressive agent and one recombinant adenovirus with a genome that includes a first recombinant DNA containing a therapeutic gene, and a second DNA containing an immunoprotective gene, for consecutive, intermittent and/or simultaneous use in in vivo and ex vivo exogenic transfections is defined.
Patent
Method for gene therapy involving suppression of an immune response
TL;DR: In this article, a method for specifically suppressing the capacity of a mammal receiving gene therapy to mount an immune response to a given expressed gene of the deficient gene in question was proposed.
Patent
Transplantation of genetically modified cells having low levels of class i mhc proteins on the cell surface
TL;DR: In this paper, the authors introduce genes encoding virus-derived MHC down-regulatory proteins for transplanting mammalian cells into a mammalian host, where the transplanted cells are expanded ex vivo, if appropriate, and transplanted into a recipient mammalian host.
References
More filters
Journal ArticleDOI
Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation.
TL;DR: The findings indicate that the ability of E3/19K to block antigen presentation is due solely to its ability to retain newly synthesized class I molecules in the endoplasmic reticulum.
Journal Article
Reduced allorecognition of adenovirus-2 infected cells.
TL;DR: The hypothesis that the E19 protein has evolved to facilitate the in vivo replication of the virus by reducing the expression of HLA class I antigens is supported.
Book ChapterDOI
Adenovirus proteins and MHC expression.
TL;DR: The study of the pathophysiological role of the MHC class I down-regulation will undoubtedly yield new insights into how the immune system combats virally infected and transformed cells.
Patent
Methods and compositions for the suppression of neu mediated transformation
Mien Chie Hung,Dihua Yu +1 more
TL;DR: In this paper, the authors proposed methods and compositions for the suppression of expression of the neu oncogene, as well as suppression of neu-oncogene-mediated transformation, tumorigenesis and metastasis.